RE:BioNTech reports on early solid tumor CAR-T cell therapy“CAR-T progress in solid tumors has been hampered by several key challenges, including difficulty in identifying a safe and effective target in tumors that are often heterogeneous - as well as maintaining an adequate T-cell response in the setting of a hostile tumor microenvironment,” said Vincent K. Lam, MD, of Johns Hopkins Medicine.
https://www.obroncology.com/conference-news/car-t-vaccine-combo-shows-promise-against-solid-tumors
[ONCY is demonstrating that it is able to overcome the above challenges faced by CAR-T therapy in solid tumors]